ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0282

5-Year Cardiovascular Event Risk in Early Rheumatoid Arthritis Patients Who Received Treat-to-Target Management: A Population-based Cohort Study
Abstract Number: 0283

Cardiovascular Risk Management in Patients with Rheumatoid Arthritis: A Single-centered Cross-sectional Study
Abstract Number: 0284

Risk Factors for Dementia in Patients with Incident Rheumatoid Arthritis: A Population-based Cohort Study
Abstract Number: 0285

Risk of Cardiovascular Disease in Newly Diagnosed Rheumatoid Arthritis: A Current Risk Assessment
Abstract Number: 0286

Cardiovascular Disease Risk in Inflammatory Arthritis Patients Still Substantially Elevated in 2020
Abstract Number: 0287

20 Years Follow-up of Cardiovascular Event Risk in Rheumatoid Arthritis Compared to Diabetes
Abstract Number: 0288

Demographic, Lifestyle, and Clinical Risk Factors for Rheumatoid Arthritis-Associated Bronchiectasis: Role of RA-related Autoantibodies
Abstract Number: 0289

Developing a Score to Predict Preclinical Interstitial Lung Disease in Patients with Rheumatoid Arthritis – a Cross-Sectional Study from the ESPOIR Cohort
Abstract Number: 0290

Prevalence and Predictors of Mortality in Rheumatoid Arthritis-Related Lung Disease: Results from a Single Center Study
Abstract Number: 0291

IgA Anti-Cyclic Citrullinated Peptide Antibodies in Bronchoalveolar Lavage Fluid from Patients with Idiopathic Pulmonary Fibrosis Are Associated with Reduced Mortality
Abstract Number: 0292

Suppressed Paraoxonase-1 Activity and Elevated Oxylipins Associate with the Presence of Small Airways Disease in Patients with Rheumatoid Arthritis
Abstract Number: 0293

Increased Prevalence of Scleroderma Specific Autoantibodies in Seropositive Rheumatoid Arthritis with Lung Involvement
Abstract Number: 0294

Comparison of Factors Associated with CT-Scan Progression of Interstitial Lung Disease in Rheumatoid Arthritis and Idiopathic Pulmonary Fibrosis. Retrospective Multicenter Study of 144 Patients
Abstract Number: 0295

Weight History and Associations with Cardiovascular Risk in Patients with Rheumatoid Arthritis
Abstract Number: 0296

The Impact of Delayed Primary Sjögren’s Syndrome Diagnosis on Patient Outcomes: A Real-World Survey in the US

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].